Is Aytu Bioscience (Aytu) stock a solid choice right now?
One stock that might be an intriguing choice for investors right now is Aytu Bioscience, Inc. AYTU. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
How did Aytu BioPharma’s short interest increase in October?
Aytu Biopharma saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 1,930,000 shares, an increase of 31.3% from the October 14th total of 1,470,000 shares. Based on an average daily trading volume, of 346,800 shares, the days-to-cover ratio is presently 5.6 days.
Is Aytu Biopharma's (ATU) PE ratio good or bad?
Only 20.25% of the stock of Aytu Biopharma is held by institutions. The P/E ratio of Aytu Biopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What do you think about the Aytu collapse price?
The AYTU collapse price is well organized plan to let the company being bought at a cheap price by someone (probably Josh friends) that will make huge profit. While bogus target prices are exposed by amateur analysts and without credibility, real analysts are published. ''Stong Sell'' so all time low seems to be not done yet.
What happened AYTU Bioscience?
(Aytu BioPharma), and its shares of common stock will continue to trade on Nasdaq under the ticker "AYTU." "This merger with Neos Therapeutics transforms Aytu into a $100 million revenue specialty pharmaceutical company with annualized cost synergies of $15 million anticipated in 2022.
Is AYTU Bioscience a good stock to buy?
Aytu BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
What is happening with AYTU?
Aytu Biopharma Inc (NASDAQ:AYTU) The 2 analysts offering 12-month price forecasts for Aytu Biopharma Inc have a median target of 8.00, with a high estimate of 11.00 and a low estimate of 5.00. The median estimate represents a +1,448.29% increase from the last price of 0.52.
Did AYTU reverse split?
AYTU's second split took place on December 09, 2020. This was a 1 for 10 reverse split, meaning for each 10 shares of AYTU owned pre-split, the shareholder now owned 1 share.
Who is Josh disbrow?
Joshua Disbrow is 44, he's been the Chairman of the Board and Chief Executive Officer of Aytu BioPharma Inc since 2016.
What is Aytu Bioscience?
What is Aytu Bioscience's exclusive distribution agreement?
Aytu Bioscience casts itself as a commercial-stage specialty pharmaceutical company engaged in the development of novel products for addressing various patient needs. The company’s portfolio of products is made up of prescription products for addressing various primary care and pediatric markets.
Is AYTU exploding?
The exclusive distribution agreement comes just weeks after the company confirmed the acquisition of Innovus Pharmaceuticals. With the acquisition, Aytu Bioscience has essentially expanded its footprint into the $40 billion consumer healthcare market.
Is AYTU a surprise?
NASDAQ:AYTU is exploding in the market on the confirmation its products will be at the center of coronavirus testing in the U.S. The company has signed an exclusive distribution agreement for the commercialization of clinically validated COVID-19 rapid test.
Who is the CEO of Aytu Biopharma?
NASDAQ:AYTU breakout does not come as a surprise, given the substantial improvement in its underlying fundamentals. An exclusive distribution agreement for coronavirus test kits is a major development set to strengthen the company’s revenue base as the race to control the virus heats up.
When did AYTU merge with Neos?
Article continues below advertisement. The combined company will operate under Aytu Biopharma and the ticker symbol “AYTU.”. Aytu BioScience CEO Josh Disbrow will continue to lead the combined company, while NEOS CEO Jerry McLaughlin will join the entity’s board of directors.
About Aytu Biopharma
On December 10, 2020 , AYTU and NEOS signed an agreement to combine their businesses. The merger will likely be approved after two independent proxy advisory firms recommended that shareholders approve the transaction. Source: Pixabay.
Aytu Biopharma (NASDAQ:AYTU) Frequently Asked Questions
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist.
When was the 424B5 completed?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aytu Biopharma stock. View analyst ratings for Aytu Biopharma or view top-rated stocks.
How much did Cantor raise for Disbrow?
As mentioned in the form, fully completed by Josh Disbrow on June 7th 2021, Form 424B5. Disbrow mandated a broker, named Cantor to raise $ 30 million for the company.